Profile data is unavailable for this security.
About the company
InhaleRx Limited is an Australia-based clinical stage drug development company. The Company is focused on developing onset, inhaled therapies to address unmet medical needs in pain management and mental health sectors. The Company is focused on the development of IRX211 to treat Breakthrough Cancer Pain (BTcP), and IRX-616a to treat panic disorders. The Company’s operates through single segment that is the development of medical technologies. Its IRX-211 focuses on the management of BTcP with non-opioid, onset inhaled therapy. The Phase I clinical trials for IRX-211 have been completed. Its IRX-616a is an approved inhaled medication for panic disorder, offering a novel treatment avenue. It holds a patent that has been approved, and provisional patents have been lodged. The Company has identified some composition properties in the way the IRX211 drug device has performed and focused on developing resulting novel intellectual property in consultation with its patent attorneys.
- Revenue in AUD (TTM)837.55k
- Net income in AUD-1.33m
- Incorporated2016
- Employees--
- LocationInhalerx LtdLevel 5, 126 Phillip StreetSYDNEY 2000AustraliaAUS
- Phone+61 38395-5446
- Websitehttps://inhalerx.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hexima Ltd | 0.00 | -503.83k | 2.17m | -- | -- | -- | -- | -- | -0.0246 | -0.0246 | 0.00 | 0.0091 | 0.00 | -- | -- | -- | -26.34 | -72.86 | -28.49 | -144.87 | -- | -- | -- | -335.94 | -- | -- | 0.00 | -- | -100.00 | -- | 46.05 | -- | -- | -- |
| Argent BioPharma Ltd | 180.56k | -17.84m | 4.73m | -- | -- | -- | -- | 26.17 | -0.3292 | -0.3292 | 0.0032 | -0.1196 | 0.0272 | 0.2721 | 0.4238 | -- | -269.25 | -135.49 | -- | -380.42 | 24.06 | -45.51 | -9,882.75 | -764.45 | 0.1752 | -321.38 | -- | -- | -79.74 | -38.66 | -1.79 | -- | -70.28 | -- |
| Inhalerx Ltd | 837.55k | -1.33m | 5.42m | -- | -- | -- | -- | 6.47 | -0.006 | -0.006 | 0.0037 | -0.0041 | 0.8301 | -- | 2.50 | -- | -131.43 | -73.85 | -- | -100.32 | -- | -- | -158.33 | -369.19 | -- | -- | -- | -- | -66.38 | 21.67 | 16.21 | -- | -- | -- |
| BPH Global Ltd | 352.38k | -1.49m | 5.56m | 31.00 | -- | -- | -- | 15.78 | -0.0026 | -0.0026 | 0.0006 | -0.0014 | 0.8548 | 3.49 | 2.27 | -- | -360.76 | -76.32 | -- | -214.32 | 6.86 | 17.08 | -422.04 | -156.56 | 0.1995 | -43.14 | -- | -- | 220.43 | -13.56 | 24.87 | -- | -- | -- |
| Invion Ltd | 0.00 | -8.81m | 7.11m | 8.00 | -- | 0.8538 | -- | -- | -0.1183 | -0.1183 | 0.00 | 0.0972 | 0.00 | -- | -- | -- | -70.63 | -29.16 | -77.64 | -30.88 | -- | -- | -- | -147.34 | -- | -- | 0.00 | -- | -100.00 | -- | -56.50 | -- | -- | -- |
| Biotron Ltd | 0.00 | -318.57k | 8.11m | 4.00 | -- | 7.21 | -- | -- | -0.0004 | -0.0004 | 0.00 | 0.0004 | 0.00 | -- | -- | -- | -43.23 | -86.63 | -206.95 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 90.73 | -- | -- | -- |
| Vectus Biosystems Ltd | 18.77k | -1.78m | 8.28m | -- | -- | -- | -- | 441.24 | -0.0334 | -0.0334 | 0.0004 | -0.0048 | 0.0134 | -- | 0.0266 | -- | -126.57 | -79.19 | -247.24 | -189.44 | -- | -- | -9,468.62 | -10,165.01 | 0.9301 | -554.06 | -- | -- | -75.58 | 73.61 | 23.99 | -- | -- | -- |
| Percheron Therapeutics Ltd | 371.10k | -14.92m | 8.70m | 8.00 | -- | 0.8696 | -- | 23.44 | -0.0149 | -0.0149 | 0.0004 | 0.0092 | 0.0275 | -- | 0.2824 | -- | -110.67 | -79.28 | -153.98 | -96.61 | -- | -- | -4,021.00 | -3,694.96 | -- | -1,093.50 | 0.0026 | -- | -39.71 | 64.80 | -25.19 | -- | -6.74 | -- |
| Invex Therapeutics Ltd | 461.52k | -476.87k | 9.02m | -- | -- | 1.72 | -- | 19.54 | -0.0063 | -0.0063 | 0.0061 | 0.0698 | 0.0797 | -- | 4.92 | -- | -8.23 | -15.04 | -8.72 | -15.74 | -- | -- | -103.33 | -419.12 | -- | -- | 0.00 | -- | -72.92 | 22.74 | 70.95 | -- | -- | -- |
